Speaking to CNBC-TV18, Harish HV, partner-India Leadership Team,Grant Thornton, says there has been a significant jump in private equity (PE) deals and the interest in outbound deal continues by India Inc.

H1 inline; Cipla Medpro fully integrated: Cipla MD

Cipla MD & Global CEO Subhanu Saxena says he had signaled that the first 12-18 months in its roadmap was investing in the business for the future - particularly on people and also the pipeline to get in a position where it'll have sustainable platform for growth for the decade and beyond.

Cipla eyes strong intl growth; emerging mkts in focus

Cipla aims to focus more on international business and will strengthen its presense in US, Europe. The company is also closely eyeing emerging markets

Cipla mgmt rejig: Time to act as godfather says YK Hamied

Dr.YK Hamied, CMD, Cipla will retire with effect on March 31.Talking to CNBC-TV18 about his retirement plans, YK Hamied, CMD, Cipla says, “We now have built up a very strong senior management team and time has come to let the youngsters‘ takeover.

Cipla eyes South Africa with plans for Cipla Medpro stake

S Radhakrishnan, ED, Cipla explains to CNBC-TV18 that the company is in discussions to acquire a 51 percent stake in Cipla Medpro, South Africa for a consideration of USD 220 million. The acquisition also offers a stake in Cipla Medpro business in South Africa.

Aim to see turnover of USD 5 bn by 2020: Cipla Chairman

Cipla reported a better-than-expected second quarter earnings. In an interview to CNBC-TV18, Chairman of the company YK Hamied said that the pharma major is expecting to achieve a turnover of USD 5 billion by the year 2020.

Margins cannot be sustained at around 27.6%: Cipla

Pharma major Cipla's first quarter net profit surged 58% year-on-year to Rs 401 crore. The margin improvement was extremely healthy at around 27.6%. Pharma major Cipla's first quarter net profit surged 58% year-on-year to Rs 401 crore. The margin improvement was extremely healthy at around 27.6%.

Cipla launches anti-malarial drug in India

In an interview to CNBC-TV18, YK Hamied, chairman and managing director of Cipla says, the company is launching an anti-malarial drug in India. "Today, being the World Malaria day, we are launching a new combination drug along with our partners who are based in Geneva called DNDI," he asserts.

Cipla aims for 8-10% revenues this yr; Eyes overseas growth

YK Hamied, the CMD of Cipla is optimistic the pharma major will post a topline growth of 8-10% this fiscal.In an interview to CNBC-TV18, he says he is looking at the company's bottomline increasing by Rs 1,000 crore in FY13.

Looking to increase exports for price advantage: Cipla

Chairman and managing director of Cipla, YK Hamied, tells CNBC-TV18 that they intend to increase the ratio of exports to total sales so as to avail the benefit of higher international prices.

Will file appeal in US court on drug patent breach: Cipla

A US District Court has ordered the seizure of a drug made by Cipla and sold by Velecra. S Radhakrishnan, CFO, Cipla has clarified on CNBC-TV18 that they are in process of filing an appeal within the next 60 days.

See marginal impact on EPS, if DEPB is withdrawn: Cipla

In an interview with CNBC-TV18, S Radhakrishnan, CFO, Cipla says, DEPB related income in FY11. He further says, the company will see marginal impact on earning per share (EPS), if the scheme is withdrawn.

Cipla disappoints; says Indore SEZ to add 10% to FY12 sales

Rationalising the company's dismal performance during the quarter, chairman and managing director YK Hamied said that the special economic zone (SEZ) at Indore and higher material costs led to lower profitability. "Also, selling anti AIDS and malaria drugs to Africa at humanitarian prices too had an impact."

Cipla tells Merck your anti-AIDS drug too costly in India

Domestic pharma giant Cipla has taken the route of applying for a "voluntary license" for Merck's HIV Isentress (a generic raltegravir) saying it is not reaching needy patients in India and is prices exorbitantly.

New MAT levy to impact cash flows, says Cipla

Speaking to CNBC-TV18, S Radhakrishnan, whole-time director of pharma major Cipla said new MAT charge will impact the company's cash flows.

Dynamics of domestic market are changing: Cipla

In an interview with CNBC-TV18, S Radhakrishnan, Wholetime Director, Cipla, speaks about the results and gives his outlook going forward.

Ongoing talks with MNCs not for stake sale: Cipla

In an exclusive interview with CNBC-TV18’s Ekta Batra and Reema Tendulkar, S Radhakrishnan, Wholetime Director of Cipla denies rumours of any kind of stake sale, calling them ‘baseless’.

What is Lupin's acquisition agenda for the future?

Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.